bs-2405R [Primary Antibody]
AKR1B1 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: AKR1B1

Specificity: This antibody may have a secondary cross-reactivity with AKR1C1/2/3/4 due to a 75% sequence similarity in the corresponding immunogen regions.

Immunogen Range: 151-250/316


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 231

Swiss Prot: P15121

Source: KLH conjugated synthetic peptide derived from human AKR1B1

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
ICC(1:100-500)

Predicted Molecular Weight: 35


Cross Reactive Species: Human
Mouse
Rat

Predicted Cross Reactive Species: Dog
Cow
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Luojie Liu. et al. Aberrant expression of AKR1B1 indicates poor prognosis and promotes gastric cancer progression by regulating the AKT-mTOR pathway. AGING-US. 2023 Sep 30; 15(18): 9661C9675Read more>>
VALIDATION IMAGES

Formalin-fixed and paraffin embedded rat tongue labeled with Anti-AKR1B1 Polyclonal Antibody, Unconjugated (bs-2405R) followed by conjugation to the secondary antibody


Lane 1: Mouse Adrenal gland tissue lysates; Lane 2: Mouse Testis tissue lysates; Lane 3: Rat Adrenal gland tissue lysates; Lane 4: Rat Testis tissue lysates; Lane 5: Human HepG2 cell lysates; Lane 6: Human A549 cell lysates; Lane 7: Human U87MG cell lysates probed with AKR1B1 Polyclonal Antibody, Unconjugated (bs-2405R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.